trending Market Intelligence /marketintelligence/en/news-insights/trending/G_rI9NyVwE4SRBNSscxMcw2 content esgSubNav
In This List

Shandong Luoxin Pharma shareholders approve delisting of shares

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Shandong Luoxin Pharma shareholders approve delisting of shares

Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. shareholders approved the resolution for the proposed delisting of the company's H shares from The Stock Exchange of Hong Kong Ltd.

The H shares can be traded until June 5. Trading will be suspended June 6, and the shares will be delisted June 16.

Additionally, a voluntary conditional offer by Giant Star Global (HK) Ltd. and Ally Bridge Flagship LX (HK) Ltd. for all the issued H shares became unconditional on May 29. The offer will close June 26.